Immunome Appoints Jean-Jacques Bienaimé to Board of Directors
Retrieved on:
Wednesday, November 8, 2023
Biotechnology, Pharmaceutical, Health, Oncology, Genzyme, Therapy, Commerce, University, Acquisition, Doctor of Philosophy, MBA, BIO, Incyte, Wharton School of the University of Pennsylvania, Growth, BioMarin Pharmaceutical, Retirement, Widener University Commonwealth Law School, JJ, Genentech, Cancer, Pharmacy, Patient, Jean-Jacques, Pharmaceutical Research and Manufacturers of America, Management, Genencor, Immunome
Immunome , Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Jean-Jacques “JJ” Bienaimé to its Board of Directors.
Key Points:
- Immunome , Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Jean-Jacques “JJ” Bienaimé to its Board of Directors.
- Mr. Bienaimé has over three decades of experience in the biotechnology and pharmaceutical industries, most recently serving as Chairman and Chief Executive Officer of BioMarin Pharmaceuticals.
- “Immunome is pleased to welcome JJ to the Board of Directors as we enter our next stage of growth,” stated Clay Siegall, PhD, President and Chief Executive Officer of Immunome.
- His guidance will be essential as we advance our pipeline of potential first-in-class and best-in-class targeted cancer therapies.”
“I am excited to join the Immunome Board of Directors as they work to bring transformative oncology therapeutics to the patients most in need,” commented Mr. Bienaimé.